Drug Trial Radar · NCT01057537
UMPIRE - Use of a Multidrug Pill In Reducing Cardiovascular Events
Last checked: Nov 20, 2026Latest source record: Nov 27, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,004
Actual
Start
Jun 2010
Primary completion
Jul 2012
Study completion Sep 2012
Sponsor
- Lead sponsor
- Imperial College LondonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- European Commission; Imperial College Healthcare NHS Trust; Royal College of Surgeons, Ireland; UMC Utrecht; The George Institute; Public Health Foundation of India; Dr. Reddy's Laboratories Limited, India
- First posted
- Jan 27, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
People with established cardiovascular disease need secondary prevention that addresses multiple risk factors. Complexity \& cost confer particularly difficult barriers to uptake of treatment; recovery from a stroke or heart attack typically necessitates multiple drugs for cholesterol, blood pressure and platelet function. A low-cost, fixed-dose, once-daily combination polypill, the Red Heart Pill, has been formulated by Dr Reddy's Laboratories. UMPIRE will evaluate whether provision of this polypill compared with usual medications improves adherence and clinical outcomes among high-risk patients in Europe and India. The results will be used to develop recommendations for equitable access.
Conditions
- Cardiovascular Diseases
Interventions
polypillDrug
The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill): Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.
Usual cardiovascular medicationsDrug
Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adherence to medication; self-reported current use of antiplatelet, statin and combination (≥ 2) blood pressure lowering therapyTime frame: End of trial follow-up
- Change in blood pressureTime frame: End of trial follow-up
- Change in LDL cholesterolTime frame: End of trial follow-up
Locations
7 sites in 5 countries. Site status is shown where the registry gives one.
George Institute Australia
Sydney, New South Wales, Australia
George Institute for International Health - India
Hyderabad, India
Public Health Foundation of India
New Dehli, India
Centre for Chronic Disease Control
New Delhi, India
Royal College of Surgeons in Ireland Research Institute
Dublin, Ireland
University Medical Center Utrecht
Utrecht, Heidelberglaan 100, Netherlands
Clinical Investigation Unit, International Centre for Circulatory Health, Imperial College London
Paddington, London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.